• Oyster Point raises $93m in financing round to fund DED pipeline pharmaceutical-technology
    February 28, 2019
    Princeton-based clinical stage pharma company Oyster Point has announced it has raised $93m in a Series B funding round. The investment will be used to support the development of its Dry Eye Disease (DED) portfolio....
PharmaSources Customer Service